This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 60% and 27.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Spectrum Pharmaceuticals (SPPI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 33.33% and 5.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA
by Zacks Equity Research
Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug
by Zacks Equity Research
The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.
Spectrum Pharmaceuticals (SPPI) Gets Nod for Rolvedon Injection
by Zacks Equity Research
Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.
Liminal (LMNL) Ends Development of Lead Candidate, Stock Down
by Zacks Equity Research
Based on results from an early-stage study, Liminal BioSciences (LMNL) decides to discontinue the development of its lead pipeline candidate, fezagepras.
Ultragenyx (RARE) Sells Portion of Royalty Interest for $500M
by Zacks Equity Research
Ultragenyx (RARE) sells 30% of the royalty interest receivable on future North America sales of Crysvita for $500 million. The total payments are capped at 1.45 times the purchase price.
Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study
by Zacks Equity Research
Moderna (MRNA) doses the first participant in the phase I study of its investigational mRNA vaccine, targeting the Nipah virus. It also starts a mid-stage study evaluating its Zika virus vaccine.
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
by Zacks Equity Research
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug
by Zacks Equity Research
Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.
Best Momentum Stocks to Buy for July 13th
by Zacks Equity Research
JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.
New Strong Buy Stocks for July 13th
by Zacks Equity Research
KMI, UFCS, GKOS, SPPI and BECN have been added to the Zacks Rank #1 (Strong Buy) List on July 13, 2022.
Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales
by Zacks Equity Research
Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.
Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.
Down 55.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Spectrum Pharma (SPPI)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Spectrum Pharma (SPPI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
PolarityTE (PTE) Gets FDA Nod to Begin Pivotal Ulcer Study
by Zacks Equity Research
PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cutaneous ulcers. PolarityTE plans to start enrollment in the next few months.
Do Options Traders Know Something About Spectrum Pharmaceuticals (SPPI) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.
Down 38% in 4 Weeks, Here's Why You Should You Buy the Dip in Spectrum Pharma (SPPI)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Spectrum Pharma (SPPI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Implied Volatility Surging for Spectrum Pharmaceuticals (SPPI) Stock Options
by Aditi Saraogi
Investors need to pay close attention to for Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.
Spectrum's (SPPI) NSCLC Drug Gets FDA's Fast Track Designation
by Zacks Equity Research
The FDA grants a Fast Track designation to Spectrum Pharmaceuticals' (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations.
Spectrum Pharmaceuticals (SPPI) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Spectrum Pharmaceuticals (SPPI) Jumps: Stock Rises 7%
by Zacks Equity Research
Spectrum Pharmaceuticals (SPPI) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.
Implied Volatility Surging for Spectrum (SPPI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Spectrum (SPPI) stock based on the movements in the options market lately.